货号价格

DLL-HM103B-100μg / 询价

DLL-HM103B-500μg / 询价

DLL-HM103B-500μgx2 / 询价

Biotinylated Human DLL3 Protein (Primary Amine Labeling)

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Biotinylated Human DLL3 Protein (Primary Amine Labeling) is expressed from HEK293 with His tag at the N-Terminus
It contains Ala27-Arg490 [Accession | Q9NYJ7-1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 50.4 kDa. Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.

纯度(Purity)

>95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1 EU per ug by the LAL method.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, 200 mM L-Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Biotinylated Human DLL3 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Anti-DLL3 Antibody, hFc Tag at 2 μg/ml (100 μl/Well) on the plate. Dose response curve for Biotinylated Human DLL3, His Tag with the EC50 of 17.5 ng/ml determined by ELISA.

背景(Background)

Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. DLL3 inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).

分子别名(Synonyms)

Delta3; DLL3; Pudgy; SCDO1; SCDO1delta3

文献(References)

(1) Saunders L R , Bankovich A J , Anderson W C , et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Science Translational Medicine, 2015.